NFKB1 and renal cell carcinoma: This is proven by the adenoviral expression of NF-κB inhibitor IκBα, which lowers the shuttling of NF-κΒ to the nucleus of the cell, and restores sensitivity to TRAIL in a wide panel of RCC cell lines, as shown in Figure 2 [32].